| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| NK-4-GBM | 26-03 | High grade glioma |
The NK-4-GBM (CTRIAL-IE 26-03) study has been designed to determine metabolic heterogeneity with gliomablastoma tumours and the impact upon natural killer cell metabolism and cytotoxicity in patients with suspected newly diagnosed high grade glioma with planned surgical intervention. |
DSSG Group: Central Nervous System
IMPROVE TMZ
| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| IMPROVE TMZ | 24-90 | High grade 3 and 4 Astrocytoma, Oligodendroglioma or Glioblastoma |
The IMPROVE TMZ (CTRIAL-IE 24-90) study has been designed to determine potential predisposition factors for severe haematological toxicity from temozolomide (TMZ), for patients with high grade 3 and 4 Astrocytoma, Oligodendroglioma or Glioblastoma |
Spine SABR
| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| Spine SABR | 20-03 | oligometastatic disease (OMD) or oligoprogressive disease (OPD) solid tumour spine metastases |
The Spine SABR (CTRIAL-IE 20-03) study has been designed to determine the maximum tolerated dose of stereotactic radiotherapy, to the spine, delivered in two fractions with a simultaneous integrated boost technique, for patients with oligometastatic or oligoprogressive spine disease. |